Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

PD-1 and LAG-3 dominate checkpoint receptor-mediated T cell inhibition in renal cell carcinoma.

Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran PA, Stenzl A, Rammensee HG, Gouttefangeas C.

Cancer Immunol Res. 2019 Sep 4. pii: canimm.0146.2019. doi: 10.1158/2326-6066.CIR-19-0146. [Epub ahead of print]

PMID:
31484656
2.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.

Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K.

PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301. eCollection 2019.

3.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Dec;67(12):1845-1851. doi: 10.1007/s00262-018-2244-7. Epub 2018 Sep 14.

PMID:
30218171
4.

A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex-Peptide Monomers by Flow Cytometry.

Chandran PA, Heidu S, Zelba H, Schmid-Horch B, Rammensee HG, Pascolo S, Gouttefangeas C.

Front Immunol. 2017 Feb 8;8:96. doi: 10.3389/fimmu.2017.00096. eCollection 2017.

5.

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.

Weide B, Martens A, Wistuba-Hamprecht K, Zelba H, Maier L, Lipp HP, Klumpp BD, Soffel D, Eigentler TK, Garbe C.

Cancer Immunol Immunother. 2017 Apr;66(4):441-449. doi: 10.1007/s00262-016-1944-0. Epub 2016 Dec 22.

PMID:
28008452
6.

Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.

Wistuba-Hamprecht K, Martens A, Weide B, Teng KW, Zelba H, Guffart E, Chen J, Garbe C, Newell EW, Larbi A, Pawelec G.

J Immunol. 2017 Jan 15;198(2):927-936. doi: 10.4049/jimmunol.1600875. Epub 2016 Dec 16.

7.

The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma.

Zelba H, Weide B, Martens A, Bailur JK, Garbe C, Pawelec G.

Oncoimmunology. 2015 Jan 30;4(1):e955683. eCollection 2015 Jan.

8.

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.

Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries J, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.

9.

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C.

Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.

10.
11.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D; DeCOG.

Ann Oncol. 2014 Mar;25(3):747-53. doi: 10.1093/annonc/mdt587. Epub 2014 Feb 6.

12.

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.

Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Mar 15;20(6):1601-9. doi: 10.1158/1078-0432.CCR-13-2508. Epub 2013 Dec 9.

13.

Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people.

Derhovanessian E, Maier AB, Hähnel K, Zelba H, de Craen AJ, Roelofs H, Slagboom EP, Westendorp RG, Pawelec G.

Age (Dordr). 2013 Aug;35(4):1387-99. doi: 10.1007/s11357-012-9425-7. Epub 2012 Jun 4.

14.

Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

J Clin Oncol. 2012 May 20;30(15):1835-41. doi: 10.1200/JCO.2011.40.2271. Epub 2012 Apr 23.

PMID:
22529253
15.

High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.

Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pföhler C, Pawelec G, Garbe C.

Cancer. 2010 Sep 1;116(17):4139-46. doi: 10.1002/cncr.25156.

16.

Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells.

Larbi A, Zelba H, Goldeck D, Pawelec G.

J Leukoc Biol. 2010 Feb;87(2):265-73. doi: 10.1189/jlb.0509304. Epub 2009 Nov 5.

PMID:
19892848
17.

Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation.

Larbi A, Cabreiro F, Zelba H, Marthandan S, Combet E, Friguet B, Petropoulos I, Barnett Y, Pawelec G.

Free Radic Biol Med. 2010 Jan 1;48(1):26-34. doi: 10.1016/j.freeradbiomed.2009.09.025. Epub 2009 Sep 28.

PMID:
19796677

Supplemental Content

Support Center